The graph for the last 5 days shows Atossa Therapeutics (ATOS) stock’s consistent growth. For the entire year, the present figure is the highest. The price was $3.08 on June 8, 2020, and it is now $6.07. Will this value, however, increase after the good news is announced? Let us take care of this matter.
Atossa Therapeutics (ATOS), a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines in areas of significant unmet medical needs, today announced the following final data from a phase 2 clinical trial of oral endoxyphene administered in the “window of opportunity” between breast cancer diagnosis and surgery.
Safety and tolerability: All adverse events were mild and thought to be related to the study medication. There were no variations in vital signs, physical examinations, or ECG and no departures from the norm in laboratory tests. Endoxyphene was judged safe and well-tolerated in this investigation based on these findings. The trial was called off due to the lack of negative effects. Atossa for a number of potential therapeutic advantages and indications is investigating oral administration of endoxifen in a window of opportunity or neoadjuvant therapy scenario. Avoiding surgery is one of them. Despite this encouraging news, investors should use greater caution when investing in this company.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.